Stem cell startup Magenta launches with $48.5m
Atlas and Third Rock Ventures have co-led a $48.5 million Series A for Magenta, a Boston start-up hoping to revive the stem cell field with its novel transplant platform.
Atlas and Third Rock Ventures have co-led a $48.5 million Series A for Magenta, a Boston start-up hoping to revive the stem cell field with its novel transplant platform.
Solstice Biologics, an interesting RNAi therapeutics company that has attracted attention for the wrong reasons, has raised $7.5 million, according to a regulatory filing, building on the $18 million raised last year from venBio and Aeris Capital. The San Francisco company is figuring out how to get RNAi-based drugs to cross multiple cell types to treat different […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.